Addex Therapeutics Ltd - American Depositary Shares (ADXN)

Addex Therapeutics stock surged after announcing clinical candidate selection with Indivior for substance use disorder treatment. Addex could receive up to $330 million plus royalties under the agreement, while advancing its own GABAB PAM program for chronic cough.

Addex Therapeutics announces Janssen Pharmaceuticals, a Johnson & Johnson unit, has halted ADX71149 development for epilepsy after Phase 2 data.

Addex Therapeutics just reported results for the first quarter of 2024.

It's time to dive into the biggest pre-market stock movers with all of the hottest news worth reading about on Monday morning!

Our coverage for Tuesday starts with a dive into the biggest pre-market stock movers traders will want to keep an eye on today!

Latest Phase 2 epilepsy study findings on ADX71149 adjunctive therapy for focal onset seizures. Partnered with Janssen, Addex Therapeutics evaluates treatment efficacy in patients with suboptimal response to standard care.

Pre-market stock movers are a great way to start the week as we check out all of the biggest news moving shares on Monday!